PARP1 and ovarian carcinoma: The high PARP1-inhibitory activity of RSV makes it a promising candidate for the therapy of breast and ovarian cancers having the susceptibility gene mutation (BRCAm), where the use of synthetic PARP1 inhibitors is currently recommended.